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ABSTRACT
A critical appraisal and clinical application of Song JW, Song J-K, Kim DS. Echocardiography and brain natriuretic
peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009;103(2):180-186. doi:10.1016/j.rmed.2008.11.012.
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Clinical Context
A 62-year-old woman presented to the emergency department for shortness of breath. The patient was on home
oxygen due to her chronic lung disease, but developed a rapid onset of shortness of breath. After admission to the
MICU, the patient’s medical records disclosed that she had interstitial lung disease due to idiopathic pulmonary
fibrosis (IPF), which was diagnosed by lung biopsy five years prior to this admission. IPF is a diagnosis of exclusion,
and the combination of biopsy results and previous work-up ruled-out other lung conditions in this patient. On
laboratory workup, the patient’s brain natriuretic peptide (BNP) was found to be elevated into heart failure range
at 1213 pg/mL (Age and Gender Adjusted Ratio = 19.8)1 and echocardiography showed minimal left cardiac
abnormalities, right atrial and ventricular enlargement, and pulmonary hypertension with a systolic pulmonary
artery pressure of 56 mmHg. She was later discharged with recommendations to follow up at an outpatient
respiratory clinic for open lung biopsy for two reasons, the first to confirm her diagnosis as it had been five years
since her biopsy. The second was that the pulmonary team decided her diagnosis was ambiguous; they were
convinced they should further rule-out other chronic lung diseases.

Clinical Question
Do echocardiography and BNP levels help clinicians determine the severity of disease and thus prognosis for patients with interstitial
lung disease?

Research Article
Song JW, Song J-K, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis.
Respir Med 2009;103(2):180-186. doi:10.1016/j.rmed.2008.11.012.
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Literature Review
Literature review began with articles found at PubMed.gov and through the Google search engine by combining the keywords
“interstitial lung disease” and “brain natriuretic peptide”. Analysis of the resulting literature found multiple prospective and
retrospective studies that evaluate the usefulness of BNP and pulmonary artery hypertension as prognostic indicators in chronic lung
disease. For example, Leuchte et al. evaluated 176 patients with chronic lung disease and analyzed indicators of mortality such as
mean pulmonary artery pressure using pulmonary function testing, cardiac catheterization, and stress testing.2 This research
included cases of both restrictive and obstructive pulmonary disease. The results of this study indicated that BNP was a good
prognostic indicator and screening tool for pulmonary hypertension in patients with chronic lung disease. Likewise, Andreassen et al.
evaluated the utility of BNP in an even more heterogeneous group of patients with chronic lung disease, with similar findings.3
However, many of these studies have a small sample size of patients with idiopathic pulmonary fibrosis. Also, these two studies are
too generalized to reconcile the prognostic capability of BNP in chronic lung disease; they included patients with both restrictive and
obstructive pathologies. Among several similar trials of pulmonary hypertension and BNP measurements, the criteria for
excluding/including patients with LV dysfunction were ambiguous.4 A further search of PubMed.gov, limited to idiopathic pulmonary
fibrosis, determined that the most focused study that defined the prognostic indications of elevated BNP and pulmonary
hypertension was written by Song et al. The sample size in this study was relatively large (n = 131), and patients with left ventricular
dysfunction were excluded based on sound criterion (Ejection Fraction < 50).5

Critical Appraisal
The article by Song et al. is a retrospective study of 131 patients with idiopathic pulmonary fibrosis, which falls under level 2B
evidence in accord with the Oxford Centre for Evidence Based Medicine. The study excluded all other disorders that could cause
secondary pulmonary hypertension and used patients that had BNPs and echocardiography performed within three days of one
another. Importantly, patients with a left ventricular ejection fraction less than fifty were excluded from the study.
Despite having patients that fit the criteria for idiopathic pulmonary fibrosis without left ventricular dysfunction, there are
admittedly flaws with the patient study group. Patients were selected from the Asan Medical Center in Seoul, South Korea. This
geographic distribution of patients makes the results of the study less generalizable as variations in BNP measurements and the
correlation to IPF in various races are not well studied. In addition, 73.3% of the patients in the study were males. While IPF is more
prevalent in smokers and males, this indicates that the evidence is partially biased to patients already known to have a more severe
and dominant presentation in the population. However, what’s critical is that the percentage of males with elevated systolic
pulmonary artery pressures (sPAP) and BNP ratios was consistent with the percentage of males in the study group (72.7% and 68.4%,
respectively). This indicates that there is little confounding bias present.
Furthermore, this study attempted to show an increase in mortality and decreased survival in patients with elevated sPAPs and BNP
versus patients without these prognostic indices. However, the study does not indicate whether the data was taken from patients
admitted for acute exacerbations of pulmonary dysfunction or from patients undergoing routine management of their condition.
The implications of this potential selection bias is less significant considering that the study included follow-up data collection;
patients likely returned to their baseline function or were functioning at a more diseased state at follow-up depending on their
reference disease state. Therefore, the study adjusted for survival based on disease severity, with data collected at the beginning
and end of the study.
While the study predicts increased mortality based on hazard ratios in patients with elevated sPAPs and BNP versus patients with
values that fall within normal limits, this type of analysis has its flaws. For example, the hazard ratios for sPAP and BNP ratio were
1.028 and 1.148, respectively (p-values < 0.001). Since the hazard ratio is greater than one, this data indicates that patients with
elevated BNP ratios and sPAP are more likely to die compared to patients with values within normal limits. However, the hazard
ratio has no implications regarding time to death. With only the hazard ratio at hand, data that better predicts time to death based
on survival data from a large study population is necessary for applicability in a clinical setting. While the authors highlight the
survival data based on their study population (see Song et al., Table 3), the mean survivals are not generalizable based on the small
sample size, which is discussed below.
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Upon further consideration of the importance of the small sample size, it is important to note the study’s determination of mortality
at follow-up in patients with newly developed pulmonary hypertension (PH) as determined by echocardiography. The authors state
that there is no significant difference with regard to survival in patients with newly developed PH versus those with persistently
normal PH measured at follow-up by echocardiography, which they claim was likely due to the small sample number (9 of the 36
patients found to have normal sPAPs at baseline; p = 0.061). However, 13 out of 56 patients were found to have elevated BNPs
associated with decreased survival at follow-up (p = 0.005). As a result, Song et al. could not confirm their hypothesis that a
combination of elevated sPAP and BNP were better predictors of mortality over the individual prognostic indices alone. The
combination, as noted by the authors, may in fact prove superior to either diagnostic variable alone because of the higher hazard
ratio.5 As support for this important hypothesis, in comparing groups with zero, one, or two prognostic parameters, the superiority
of the combination is highlighted by the decreasing survival rates as the number of abnormal parameters a patient has increases.
Therefore, further studies with larger sample sizes that assess the combination of both parameters are warranted.

Clinical Application
In the study by Song et al., it was concluded that patients with no prognostic indicators (elevated BNP or PH) had a
mean survival of 25.2 months. Those with one or the other had a mean survival of 14.9 months. Those with both
indices had a mean survival of 4.7 months.5 The patient previously described had a BNP and BNP ratio of 1213 and
19.8, respectively. In addition, her pulmonary artery pressure was roughly 56 mmHg. Given the two abnormal
parameters, the patient has a mean survival of 4.7 months based on the study’s survival data.5 However, the
pulmonary physicians concluded that she would require an open lung biopsy for future management.
Retrospectively, the pulmonary physicians could have used the above data to explain that with two abnormal
parameters at the patient’s baseline level of functioning, survival beyond five months is unlikely when the study’s
findings are applied to her scenario. Although not absolute, this study provides clinically applicable reasoning
regarding prognosis associated with IPF and sets up a theoretical discussion for patients uncertain of the long-term
progression of their illness.
I believe there are three points to be made regarding this patient and the above evidence. First, based on the
patient’s elevated BNP and sPAP, one must surmise that this particular patient has already developed severe,
irreversible complications of her respiratory illness and requires no further work-up. Yet, her prognosis was
overlooked and further work-up was sought because the pulmonary team decided her diagnosis was ambiguous.
Second, and what I took away from this experience, is that when determining future management of patients with
idiopathic pulmonary fibrosis and other interstitial lung disease based on BNP and PH, physicians should utilize
these indices in the context of the patient’s overall physical and mental health. For example, over the course of
this patient’s hospital stay, her care team discovered that she had poor follow-up with both her primary care
provider and specialists for her lung disease. With the pulmonary team unconvinced by a diagnosis of IPF based on
previous biopsy results, it was as if her physicians were giving her a false sense of a long life expectancy. Yet, the
patient’s quickly deteriorating health will likely hinder a follow-up with her respiratory specialist as she will likely
need more acute care. Simply put, the team treated the disease, not the patient. Lastly, and as advice for future
physicians, utilize these opportunities to build rapport with patients. Evidence-based medicine based on data
obtained from studies such as Song et al. allows one to utilize prognostic indices to have difficult conversations
with patients. These conversations strengthen the patient-physician relationship. In the case of this particular
patient, her prognosis was hampered by a focus on treating her disease and a critical patient-centered discussion
was left to follow-up.
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